Protica Bio is a groundbreaking start-up that combines cutting-edge proteomics technology and machine learning to enhance cancer immunotherapy and revolutionize diagnostic prediction and treatment. By utilizing a proprietary platform developed by a leading expert in Mass spectrometry, Protica Bio aims to improve clinical decisions in immunotherapy and discover new drug targets. Their approach involves integrating deep proteomics with machine learning to create diagnostic capabilities and enhance response rates for current and future treatments.

With the need to improve response rates in immune checkpoint inhibitor therapy for solid tumors, Protica Bio focuses on identifying predictive markers of response and novel drug targets for combination therapies. By leveraging state-of-the-art proteomics technologies and computational biology, the company aims to achieve breakthroughs in this domain.

Protica Bio is led by a team of highly skilled professionals, including Dr. Olga Nissan, the Founder & CEO, who brings rich leadership experience in R&D and clinical teams. The team also includes experts in clinical cancer proteomics, biochemistry, pharmacology, pathology, immunology, and computational biology, ensuring a multidisciplinary approach to their innovative research.

If you are interested in contributing to their research and technology, Protica Bio offers exciting career opportunities. Contact them at [email protected] to join the revolution in cancer immunotherapy and diagnostic prediction.